Treating myeloma cast nephropathy without treating myeloma
Nelson Leung
Nelson Leung
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(5):1605-1608. doi:10.1172/JCI63248.
View: Text | PDF
Category: Commentary

Treating myeloma cast nephropathy without treating myeloma

Abstract

Cast nephropathy is the result of coprecipitation of immunoglobulin free light chains (FLCs) with Tamm-Horsfall glycoprotein (THP). It is a hallmark of multiple myeloma that has significant consequences. Treatment strategies in the past focused on reduction of serum FLC by control of the myeloma. In this issue, Ying et al. report on their successful synthesis of a cyclized competitor peptide that blocks the binding of FLC to THP. In animal studies, this cyclized peptide was capable of reducing cast formation and kidney injury, representing a novel treatment strategy for cast nephropathy that does not depend on the responsiveness of the myeloma to chemotherapy.

Authors

Nelson Leung

×
Options: View larger image (or click on image)
Treatment of cast nephropathy by targeting THP and FLC interaction. (A) ...

Figure 2

Treatment of cast nephropathy by targeting THP and FLC interaction.

(A) Excessive monoclonal FLC is filtered and binds with THP in the ascending limb of the loop of Henle, resulting in obstruction and cast nephropathy. (B) In the presence of cyclized competitor peptide (CCP), the binding site of THP is blocked, thus preventing FLC from binding and coprecipitation with it. FLC and THP both pass freely through the nephron.